Virtu KCG Holdings’s Rosetta Genomics Ltd. ROSG Stock Holding History

Virtu KCG Holdings’s Portfolio ROSG Stock Details ROSG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-11,425	Closed	-$34K	–	3921
2017 Q1	$34K	Buy	11,425 +6,127	+116%	+$33K	﹤0.01%	2909
2016 Q4	$27K	Buy	5,298 +3,272	+162%	+$25K	﹤0.01%	3202
2016 Q3	$20K	Sell	2,026 -58	-3%	-$705	﹤0.01%	2921
2016 Q2	$29K	Sell	2,084 -2,926	-58%	-$41.7K	﹤0.01%	2758
2016 Q1	$66K	Buy	5,010 +3,226	+181%	+$41.1K	﹤0.01%	2406
2015 Q4	$26K	Buy	+1,784	New	+$38.5K	﹤0.01%	3273
2015 Q3	–	Sell	-1,750	Closed	-$71K	–	4134
2015 Q2	$71K	Sell	1,750 -201	-10%	-$8.6K	﹤0.01%	3006
2015 Q1	$72K	Buy	+1,951	New	+$73.9K	﹤0.01%	2739
2014 Q3	–	Sell	-853	Closed	-$44K	–	4374
2014 Q2	$44K	Sell	853 -935	-52%	-$46.3K	﹤0.01%	3447
2014 Q1	$107K	Sell	1,788 -140	-7%	-$7.23K	﹤0.01%	3198
2013 Q4	$66K	Buy	+1,928	New	+$66.9K	﹤0.01%	3545

Other funds holding ROSG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HCM

Highlander Capital Management Short Hills, New Jersey $292M AUM 22.24% 1-Year Est. Return

SEI Investments Oaks, Pennsylvania $108B AUM 26.14% 1-Year Est. Return

Virtu KCG Holdings's ROSG Position: Q2 2017 in Review

Virtu KCG Holdings sold out of Rosetta Genomics Ltd. (ROSG) in Q2 2017, closing a stake of 11,425 shares — an estimated $34K sold.

Virtu KCG Holdings first reported a position in ROSG in Q4 2013 and held it in 11 quarters. The position peaked at $107K in Q1 2014. 6 funds tracked by Wall St. Rank hold ROSG as of Q2 2017.

Virtu KCG Holdings reported no remaining Rosetta Genomics Ltd. position as of Q2 2017 after selling out during the quarter.
Virtu KCG Holdings sold 11,425 Rosetta Genomics Ltd. shares in Q2 2017, an estimated $34K.
Virtu KCG Holdings first reported a position in Rosetta Genomics Ltd. in Q4 2013 and held it in 11 quarters.
Virtu KCG Holdings's Rosetta Genomics Ltd. position peaked at $107K in Q1 2014.
6 funds tracked by Wall St. Rank held Rosetta Genomics Ltd. as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.